Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
- Conditions
- AML, Adult
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 3
- Registration Number
- NCT05601466
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
- Conditions
- Minimal Residual Disease
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 1
- Registration Number
- NCT05601830
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 115
- Registration Number
- NCT05600855
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 40
- Registration Number
- NCT05599256
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
- Conditions
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-10-05
- Target Recruit Count
- 60
- Registration Number
- NCT05594784
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts
- Conditions
- Previously Treated Primary Immune Thrombocytopenia
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-04-24
- Target Recruit Count
- 157
- Registration Number
- NCT05583838
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳the Second Hospital of HeBei Medical University, Shijiazhuang, Hebei, China
🇨🇳North China University of Science and Technology Affiliated Hospital, Tangshan, Heibei, China
ctDNA Methylation Sequencing for Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Other: plasma circulation DNA methylation sequencing
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Target Recruit Count
- 66
- Registration Number
- NCT05578625
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2022-10-07
- Target Recruit Count
- 39
- Registration Number
- NCT05571332
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 20
- Registration Number
- NCT05562882
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2022-09-22
- Target Recruit Count
- 32
- Registration Number
- NCT05549973
- Locations
- 🇨🇳
InstituteHBDH, Tianjin, Tianjin, China